Drugs / [18F]flumazenil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04308954 | Nov 2016 → Dec 2018 | fragile X syndrome | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]flumazenil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04308954 ↗ |
| Modality | Diagnostic / imaging agent | “is a PET radiopharmaceutical” NCT04308954 ↗ |